HENAN LINGRUI PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.21 CNY | -0.66% |
|
-2.34% | +41.50% |
| May. 13 | Lingrui Pharma Gets Green Light to Market Type 2 Diabetes Drug | MT |
| Apr. 25 | Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2024 * | 3.75B 518M | Sales 2025 * | 4.38B 605M | Capitalization | 13.65B 1.89B |
|---|---|---|---|---|---|
| Net income 2024 * | 684M 94.46M | Net income 2025 * | 780M 108M | EV / Sales 2024 * | 3.64 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.12 x |
| P/E ratio 2024 * |
20
x | P/E ratio 2025 * |
17.6
x | Employees | 2,530 |
| Yield 2024 * |
3.63% | Yield 2025 * |
4.25% | Free-Float | 77.13% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.66% | ||
| 1 week | -2.34% | ||
| 1 month | -4.87% | ||
| 3 months | +20.57% | ||
| 6 months | +41.50% | ||
| Current year | +41.50% |
1 week
24.05
25.60
1 month
24.0526.89
Current year
16.1526.89
1 year
14.3026.89
3 years
9.3026.89
5 years
7.6626.89
10 years
5.8826.89
| Managers | Title | Age | Since |
|---|---|---|---|
Wei Xiong
CEO | Chief Executive Officer | 40 | - |
Peng Yu
DFI | Director of Finance/CFO | 55 | - |
Jia Shu Jiang
BRD | Director/Board Member | 51 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wei Xiong
CEO | Chief Executive Officer | 40 | - |
Xi Zhen Wu
BRD | Director/Board Member | 60 | 06-04-17 |
Jun Yang
BRD | Director/Board Member | 55 | 23-05-17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 112 M€ | +4.61% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 24.21 | -0.66% | 5,574,400 |
| 24-05-30 | 24.37 | -.--% | 5,597,860 |
| 24-05-29 | 24.37 | -2.09% | 9,935,000 |
| 24-05-28 | 24.89 | -1.89% | 6,793,957 |
| 24-05-27 | 25.37 | +2.34% | 7,099,200 |
End-of-day quote Shanghai S.E., May 30, 2024
More quotes
Henan Lingrui Pharmaceutical Co., Ltd is a China-based company, principally engaged in the research and development, production and distribution of medicines. The Company's products include emplastrum, tablets, capsules, ointments and others, applied in the treatment of diabetes mellitus, osteoarthritis, gastropathy, cardiovascular and cerebrovascular diseases, respiratory disease, gynecopathy and dermatopathy, among others. The Company distributes its products throughout China, with Henan Province and Beijing as its major markets.
Sector
Pharmaceuticals
Calendar
2024-08-20
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
24.21
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +41.50% | 1.89B | |
| +37.29% | 6.02B | |
| -21.28% | 4.19B | |
| +4.52% | 3.25B | |
| -18.16% | 2.87B | |
| -7.70% | 2.37B | |
| -4.05% | 1.58B | |
| -15.56% | 1.54B | |
| -14.62% | 1.5B | |
| +40.06% | 1.45B |
- Stock Market
- Equities
- 600285 Stock
